CGRP1 Antibody (4) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-00519
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human, Rat
Applications
ELISA, Immunohistochemistry, Immunohistochemistry-Paraffin
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 kappa Clone # 4
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Synthetic human alpha-CGRP
Epitope
The epitope lies within residues 19-37 of human alpha-CGRP.
Specificity
This antibody binds human alpha-CGRP. Based on inhibition ELISA, this antibody cross-reacts up to 12% with human beta-CGRP and human amylin, while there is little (
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1 kappa
Description
CULTURE MEDIUM: RPMI 1640 with 10% fetal calf serum FUSION PARTNER: SP2mIL6 IMMUNIZATION: Female NMRI x BALB/c mice immunized by intraperitoneal injection
Scientific Data Images for CGRP1 Antibody (4) - BSA Free
Immunohistochemistry-Paraffin: CGRP1 Antibody (4) - BSA Free [NBP3-00519]
Immunohistochemistry-Paraffin: CGRP Antibody (4) - BSA Free [NBP3-00519] - Paraffin embedded rat tissue stained with CGRP Antibody (4) - BSA Free diluted 1:400 in 1% BSA/PBS and incubated overnight.Applications for CGRP1 Antibody (4) - BSA Free
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
ELISA: NBP3-00519 binds free human a-CGRP in solution. NBP3-00519 (as biotinylated detection antibody) forms a sandwich ELISA pair with NBP3-00518 (as capture antibody) for measuring human a-CGRP, giving a detection limit of 0.13 nmol/L in an unoptimized buffer assay.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
10mM Phosphate (pH 7.4) and 0.5M NaCl
Format
BSA Free
Preservative
0.9% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CGRP1
Signaling of CGRP and its receptor are involved in vasodilation, neurogenic inflammation, and peripheral sensitization of nociceptors, all of which relate to migraine pathophysiology (2-3). Studies have found that CGRP is both released during migraines and can also induce migraines (3-5). Under normal conditions CGRP levels are typical and neurotransmission is relative; however, migraine triggers including light and sound can increase CGRP levels, enhance neurotransmission, and alter the pain and sensory aversions associated with migraines (2). Given its role, CGRP and its receptor have been the target of many migraine therapeutics including small molecule agonists called gepants and monoclonal antibodies (3-5). Ubrogepant and Rimegepant, two small molecule CGRP receptor agonists, have been FDA approved while another agonist, Atogepant, is ongoing in clinical trials (3,5). Additionally, four monoclonal antibodies against either CGRP or its receptor that are used to block signaling have been FDA approved: Eptinezumab, Fremanezumab, Galcanezumab, and Erenumab (3-5).
References
1. Russell, F. A., King, R., Smillie, S. J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene-related peptide: physiology and pathophysiology. Physiological reviews, 94(4), 1099-1142. https://doi.org/10.1152/physrev.00034.2013
2. Russo A. F. (2015). Calcitonin gene-related peptide (CGRP): a new target for migraine. Annual review of pharmacology and toxicology, 55, 533-552. https://doi.org/10.1146/annurev-pharmtox-010814-124701
3. Wattiez, A. S., Sowers, L. P., & Russo, A. F. (2020). Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. Expert opinion on therapeutic targets, 24(2), 91-100. https://doi.org/10.1080/14728222.2020.1724285
4. Deen, M., Correnti, E., Kamm, K., Kelderman, T., Papetti, L., Rubio-Beltran, E., Vigneri, S., Edvinsson, L., Maassen Van Den Brink, A., & European Headache Federation School of Advanced Studies (EHF-SAS) (2017). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain, 18(1), 96. https://doi.org/10.1186/s10194-017-0807-1
5. de Vries, T., Villal0n, C. M., & MaassenVanDenBrink, A. (2020). Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacology & therapeutics, 211, 107528. https://doi.org/10.1016/j.pharmthera.2020.107528
Long Name
Calcitonin Gene Related Peptide I
Alternate Names
a-CGRP, alpha-CGRP, CGRP 1, CGRP alpha, CGRP I
Gene Symbol
CALCA
Additional CGRP1 Products
Product Documents for CGRP1 Antibody (4) - BSA Free
Product Specific Notices for CGRP1 Antibody (4) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...